Dr. William Biggs has, over the past several years, played a key role in establishing several high volume regulated clinical testing laboratories. Most recently, Dr. Biggs joined Human Longevity Inc (HLI) as the Head of Sequencing Operations in March of 2014. The goal of HLI is to drive the incorporation of genetic information, both human and Microbiome into the regular medical decision management. While at HLI William was responsible for assembling a team of over 20 highly skilled individuals that manned both Technology Development and CLIA-certified Production Sequencing laboratories. The assembled team has, over the past four years has sequenced over 40,000 human genomes and 6,000 microbiomes.
Prior to joining HLI, William joined newly created Clinical Research Sequencing Platform (CRSP) at the Broad Institute of MIT and Harvard as the Director of Clinical Sequencing in July 2013. The goal of CRSP was to support pivotal clinical diagnostic, research and trials efforts to identify applications for deep sequencing in the process of medical decision-making. A further goal of CRSP is to assist in the assembly of an evidence base required for broad based reimbursement and utilization of deep sequencing in patient management.
Prior to joining the Broad that William was the Director of Genetics and Genomics at Aviir Diagnostic Laboratories. Prior joining Aviir, William as Director of Technical Operations, was a member of the founding team at Affymetrix Clinical Service Laboratories.
William obtained his Ph.D. in Biological Chemistry from UCLA in 1994 and has extensive experience in elucidating the roles of genetics, signal transduction and transcriptional regulation during the initiation of progression of disease gained during studies conducted at The Salk Institute, The Ludwig Institute for Cancer Research, and Ambit Biosciences.